Fabricating polydopamine-coated MoSe2-wrapped hollow mesoporous silica nanoplatform for controlled drug release and chemo-photothermal therapy
Song Chai,1,* Shifeng Kan,1,* Ran Sun,1 Ruijuan Zhou,1 Yi Sun,2 Wenhua Chen,1 Bo Yu1,3 1Department of Rehabilitation, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai 200080, China; 2Department of Rehabilitation, Shanghai Sunshine Rehabilitation Center, Yangzhi Affiliated Rehabilit...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/385c43a7cefd4e5b846f7903514ad419 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Song Chai,1,* Shifeng Kan,1,* Ran Sun,1 Ruijuan Zhou,1 Yi Sun,2 Wenhua Chen,1 Bo Yu1,3 1Department of Rehabilitation, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai 200080, China; 2Department of Rehabilitation, Shanghai Sunshine Rehabilitation Center, Yangzhi Affiliated Rehabilitation Hospital of Tongji University, Shanghai 201209, China; 3Department of Rehabilitation Therapy, School of International Medical Technology, Shanghai Sanda University, Shanghai 201209, China *These authors contributed equally to this work Background: Integration of several types of therapeutic agents into one nanoplatform to enhance treatment efficacy is being more widely used for cancer therapy. Methods: Herein, a biocompatible polydopamine (PDA)-coated MoSe2-wrapped doxorubicin (DOX)-loaded hollow mesoporous silica nanoparticles (HMSNs) nanoplatform (PM@HMSNs-DOX) was fabricated for dual-sensitive drug release and chemo-photothermal therapy for enhancing the therapeutic effects on breast cancer. The HMSNs were obtained by a “structural difference-based selective etching” strategy and served as the drug carrier, exhibiting a high DOX loading capacity of 427 mg/g HMSNs-NH2, and then wrapped with PDA-coated MoSe2 layer to form PM@HMSNs-DOX. Various techniques proved the successful fabrication of the nanocomposites. Results: The formed PM@HMSNs-DOX nanocomposites exhibited good biocompatibility, good stability, and super-additive photothermal conversion efficiency due to the cooperation of MoSe2 and PDA. Simultaneously, the pH/near-infrared-responsive drug release profile was observed, which could enhance the synergistic therapeutic anticancer effect. The antitumor effects of PM@HMSNs-DOX were evaluated both in vitro and in vivo, demonstrating that the synergistic therapeutic efficacy was significantly superior to any monotherapy. Also, in vivo pharmacokinetics studies showed that PM@HMSNs-DOX had a much longer circulation time than free DOX. In addition, in vitro and in vivo toxicity studies certified that PM@HMSNs are suitable as biocompatible agents. Conclusion: Our nanoplatform loaded with DOX displays pH/near-infrared-induced chemotherapy and excellent photothermal therapy, which hold great potential for cancer treatment. Keywords: hollow mesoporous silica nanoparticles, MoSe2, polydopamine, chemo-photothermal therapy |
|---|